Point-of-Care Detection Readout Patents: Who Leads 2026
- Filing peaked in 2021 at 24 records and fell to 2 by 2024, a -92% drop across that three-year span — the field's most active claim-staking window has already closed.
- The top 5 assignees hold 45.7% of all 175 records in scope, and the top 10 hold 66.9% — this is a concentrated field with a long tail below it.
- G01N appears in 68.6% of records while C12Q appears in 42.3% — most filings pair general material-analysis claims with nucleic-acid measurement claims rather than choosing one.
Filing growth compares 2021 (24 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 175 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This review covers 175 published patent records matching point-of-care detection readout: lateral flow strips, fluorescence and colorimetric signal capture, smartphone imaging, and reader calibration tied to limit-of-detection claims. The scope spans filings from 2015 through the 2026-07-31 data cut-off, with the usual caveat that the most recent one to two years understate true filing activity because publication lags filing by roughly 18 months.
The dataset sits at the intersection of assay chemistry and signal capture hardware — claims range from lateral-flow strip chemistry to smartphone-camera calibration routines, which is why the IPC composition below spreads across both G01N material-analysis classes and C12Q nucleic-acid measurement classes rather than concentrating in one.
Filing trend and technology composition
Two views of the same 175 records: how filing activity moved year over year, and which IPC subclasses carry the claims.
Filing trend, 2017-2026
Filing rose to a peak of 24 records in 2021, then declined sharply; 2021-to-2024 shows a -92% drop (24 to 2), the last span long enough to be read as a complete trend given publication lag. Years after 2024 are still filling in and should not be read as a continued decline.
IPC subclass composition
G01N (material analysis and testing) appears in 68.6% of the 175 records and C12Q (enzyme/DNA measurement) in 42.3% — the two most common classes overlap in many records, since a single filing often claims both the physical readout mechanism and the biochemical assay it reads. Smaller classes such as B01L and C12M each sit near 6.9%, marking narrower apparatus claims rather than core readout chemistry.
Shares are the percentage of the 175 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Detection Readout for Point-of-Care Molecular Tests with Eureka
This page is one run against one query. Ask Eureka your own question about detection readout for point-of-care molecular tests and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing
Isothermal nucleic acid amplification reactor with integrated solid state membrane
Provided are devices adapted to isolate, amplify, and detect nucleic acids that may be present in a biological sample. The devices can, in some embodiments, isolate, amplify, and detect nucleic acid in a single chamber. In other embodiments, the devices are adapted to isolate and amplify nucleic acids in a reaction chamber, after which the nucleic acids may be communicated to a pervious medium — such as a lateral flow strip — where the user may label and detect the nucleic acids.Filed by New York University; the claims tie amplification chemistry directly to a lateral-flow readout step in a single device, which is the structural pattern much of this landscape builds on or around.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20070218459A1 | Diagnostic System For Otolaryngologic Pathogens And Use Thereof | 126 |
| 2 | US20080193965A1 | Microorganism detection and analysis using carbohydrate and lectin recognition | 94 |
| 3 | US20110136262A1 | Integrated microchip sensor system for detection of infectious agents | 37 |
| 4 | US20130315782A1 | Biochip and fabrication thereof | 35 |
| 5 | US20140162244A1 | Isothermal nucleic acid amplification reactor with integrated solid state membrane | 24 |
| 6 | US20180036727A1 | Apparatuses and methods for pathogen detection using microfluidic biochips | 23 |
| 7 | US8088596B2 | Method of microorganism detection using carbohydrate and lectin recognition | 23 |
| 8 | US20130089858A1 | Molecular diagnostic assay device and method of use | 18 |
| 9 | WO2013040435A2 | Molecular diagnostic assay device and method of use | 15 |
| 10 | WO2013103360A1 | Isothermal nucleic acid amplification reactor with integrated solid state membrane | 10 |
Citation counts favour older filings simply because they have had more time to accumulate citations within this corpus — treat them as a signal of influence on the field, not of current filing activity.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the raw counts are read against each other.
A concentrated field with a long tail
The top 5 assignees hold 45.7% of all 175 records and the top 10 hold 66.9% — well above half the field sits with a small number of repeat filers, while the remaining 83 ranked companies split what is left, many with a single filing each.
The peak filing window has passed
Filing activity peaked at 24 records in 2021 and dropped -92% to 2 records by 2024, the last year with a complete-enough publication window to trust. That does not mean the technology is exhausted — it means the claim-staking rush around lateral-flow and smartphone-imaging readout largely happened in the 2019-2022 period.
Readout and assay chemistry claims overlap
G01N (material analysis) and C12Q (enzyme/DNA measurement) are the two dominant classes, at 68.6% and 42.3% of records respectively. Because a record can carry both, most substantive filings bundle the physical detection mechanism with the underlying molecular assay rather than claiming either alone.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to detection readout for point-of-care molecular tests, with the prior art for and against each one.
Who holds the claims
The assignee ranking covers 83 companies and research institutions counted by record; it is the complete list the data endpoint returns, not a curated top 50.
One filer well ahead of the field
The leading assignee holds 27 of the 175 records, more than double the fifth-place count of 10 — a gap wide enough to suggest a deliberate, sustained filing programme rather than opportunistic filing.
A gradual drop-off, not a cliff
Fifth place holds 10 records and tenth place holds 6 — the decline from top to tenth is steady rather than sharp, meaning the top 10 combined (117 records, 66.9% of all 175) is a genuinely useful boundary for competitive tracking.
A handful of recurring co-filing relationships
Ten co-assignee pairs recur across the dataset, with the strongest pairing appearing across 12 shared records — evidence of sustained university-industry or inter-institutional collaboration rather than one-off joint filings.
| Assignee | Recent year | YoY |
|---|---|---|
| Credo Biomedical Pte Ltd | 0 | — |
| The Regents of the University of California | 0 | — |
| The University of Queensland | 0 | — |
| Seattle Biomedical Research Institute | 0 | — |
| Palogen Inc | 0 | — |
| NLC Pharma Ltd | 0 | — |
| March Therapeutics Inc | 0 | — |
| DXLAB INC | 0 | — |
Where to take this next
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or new filing.
Map the top 10 assignees' active claims
With 66.9% of records held by 10 filers, a freedom-to-operate review gets most of its value from this group before it looks at the long tail.
Explore assignee claims in EurekaTest the under-claimed sub-areas
Calibration drift correction and multiplexed colorimetric separation show thin filing density against the core readout claims — worth a novelty check before drafting.
Run a white space search in EurekaWatch for the 2025-2026 filing catch-up
Publication lag means 2025-2026 records are still arriving; re-run this landscape in six to twelve months to see whether filing activity resumes above the 2024 low.
Set a monitoring alert in EurekaCommon questions on this landscape
The ranked assignee list covers 83 companies and institutions across the 175 records in scope, with a single leading filer holding 27 records — more than double the fifth-place count of 10. The top 5 assignees together hold 45.7% of all records, and the top 10 hold 66.9%, so the field is concentrated at the top with a long tail of single- or double-filing entrants below it. Anyone doing competitive tracking should focus on the top 10 first, since that group accounts for two-thirds of all filings in scope.
No — filing peaked at 24 records in 2021 and fell to 2 records by 2024, a -92% drop across that three-year span, which is the last period long enough to be read reliably given publication lag. Records from 2025 onward are still filling in and understate true activity, so it is too early to call the field dead, but the peak claim-staking window has clearly passed. A resurgence would show up first as a rebound in 2025-2026 counts once those years finish publishing.
G01N (material analysis and testing) appears in 68.6% of the 175 records, making it the single most common classification, followed by C12Q (enzyme and DNA measurement) at 42.3%. Because records can carry multiple IPC codes, these two classes overlap heavily — most substantive filings claim both the physical detection mechanism and the underlying molecular assay together. Smaller classes like B01L (lab apparatus) and C12M (bioreactors) each sit around 6.9%, covering narrower apparatus-level claims.
Sub-areas like multiplexed colorimetric channel separation, reader-side calibration drift correction, and enzyme-free isothermal signal amplification readout show thin filing density relative to the dominant lateral-flow and fluorescence readout claims. These are not unclaimed entirely, but the claim density is low enough that a carefully scoped filing has room to establish a defensible position. Any white-space filing should still be checked against the top 10 assignees' portfolios, since dominant filers sometimes hold broad claims that reach into adjacent sub-areas.
US20140162244A1, assigned to New York University, claims a device that isolates, amplifies, and detects nucleic acids in a single chamber, with an alternative embodiment that routes amplified nucleic acid to a lateral-flow strip for labelling and detection. This structural pattern — amplification chemistry feeding directly into a lateral-flow readout step within one device — recurs across much of this landscape, making the patent a useful reference point for freedom-to-operate analysis even though it is only one of 175 records. New entrants building integrated amplify-and-read devices should map their claim scope against it specifically, not just against the field's most-cited records generally.
Research Detection Readout for Point-of-Care Molecular Tests in depth with Eureka
Go past this page: query the whole detection readout for point-of-care molecular tests corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.